Back to results
US 2026/0216204 A1Published application
Methods for treating lower risk myelodysplastic syndrome
AssigneeConstellation Pharmaceuticals, Inc.
InventorsKatarina Luptakova, Stefan Haertle
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of pelabresib, and pharmaceutically acceptable salts and hydrates thereof, for treating lower risk myelodysplastic syndrome (LR-MDS) and conditions associated therewith.
Claims36
A method of treating lower-risk myelodysplastic syndrome (LR-MDS) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of pelabresib, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.